Boron Neutron Capture Therapy Market Report 2026

The boron neutron capture therapy market size has grown rapidly in recent years. It will grow from $0.12 billion in 2025 to $0.15 billion in 2026 at a compound annual growth rate (CAGR) of 17.5%. The growth in the historic period can be attributed to increasing prevalence of cancer cases, early development of neutron capture research, adoption of reactor-based radiation therapies, growth in oncology clinical research, rising government funding for cancer treatment studies.

The boron neutron capture therapy market size is expected to see rapid growth in the next few years. It will grow to $0.28 billion by 2030 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to growing adoption of precision medicine approaches, increasing shift toward targeted cancer therapies, expansion of accelerator-based BNCT systems, rising investment in oncology R&D infrastructure, increasing regulatory approvals for advanced radiotherapy techniques. Major trends in the forecast period include rising adoption of accelerator-based BNCT systems, growing use of next-generation boron delivery agents, increasing focus on precision oncology treatment methods, expansion of neutron beam optimization technologies, rising clinical trials for brain and extracranial tumor applications.

The growing worldwide incidence of cancer is anticipated to propel the expansion of the boron neutron capture therapy market going forward. Cancer is a medical condition in which abnormal cells proliferate uncontrollably and spread throughout the body, disrupting and damaging normal tissues. The increasing occurrence of cancer is driven by lifestyle-related risk factors such as tobacco consumption, unhealthy dietary patterns, and physical inactivity, which contribute to chronic inflammation and genetic mutations that elevate cancer risk over time. Boron neutron capture therapy contributes to cancer treatment by offering a targeted radiation-based approach that selectively eradicates tumor cells while minimizing harm to surrounding healthy tissues, thereby supporting its suitability for complex or recurrent cancer cases. For instance, in February 2024, according to the World Health Organization, a Switzerland-based global health agency, over 35 million new cancer cases are projected in 2050, representing a 77% increase from the estimated 20 million cases recorded in 2022. Therefore, the growing global prevalence of cancer is driving the expansion of the boron neutron capture therapy market.

Leading companies operating in the boron neutron capture therapy market are focusing on advancing novel boron delivery agents to enhance tumor targeting, improve imaging accuracy, and support effective therapeutic outcomes. Novel boron delivery agents are specialized compounds engineered to selectively deliver and concentrate boron in tumor cells, enhancing precision and therapeutic effectiveness in boron neutron capture therapy. For example, in January 2025, Neuboron Medtech Ltd., a China-based R&D-oriented medical technology company, achieved IND approval for ¹⁸F-BPA, marking a key regulatory milestone in BNCT development. This highlights a rare combination of regulatory progress and clinical advancement, accelerating the translation of BNCT from research to real-world oncology applications.

In November 2024, TAE Life Sciences, a US-based provider of boron neutron capture therapy technology, entered into a strategic collaboration with Stella Pharma Corporation to advance BNCT development. Through this collaboration, both companies aim to accelerate the development and global deployment of boron neutron capture therapy solutions. Stella Pharma Corporation is a Japan-based provider of boron-based pharmaceutical products and cancer treatment drugs, including boronophenylalanine formulations utilized in boron neutron capture therapy for targeted cancer treatment.

Major companies operating in the boron neutron capture therapy market are Hitachi Ltd., Mitsubishi Heavy Industries Ltd., Sumitomo Heavy Industries Ltd., RaySearch Laboratories AB, Toshiba Energy Systems & Solutions Corporation, Cancer Intelligence Care Systems Inc., Neuboron Medtech Ltd., TAE Life Sciences LLC, Neutron Therapeutics Inc., Katchem Ltd., Stella Pharma Corporation, Fukushima SiC Applied Engineering Inc., International Particle Therapy Inc., Aviko Radiopharmaceuticals Sp. z o.o., Helsinki University Hospital, University of Wisconsin-Madison.

Asia-Pacific was the largest region in the boron neutron capture therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the boron neutron capture therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the boron neutron capture therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The boron neutron capture therapy market consists of revenues earned by entities by providing services such as targeted cancer treatment using neutron irradiation, patient treatment planning, neutron beam delivery, and clinical oncology services related to boron neutron capture therapy (BNCT). The market value includes the value of related goods sold by the service provider or included within the service offering. The boron neutron capture therapy market also includes sales of boronophenylalanine (bpa), sodium borocaptate (bsh), neutron beam accelerator system, neutron beam accelerator system and research nuclear reactor systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.